The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2024 and forecasted to 2033

As per The Business Research Company’s Filgrastim Biosimilars Global Market Report 2024, the filgrastim biosimilars market is expected to show significant growth in the forecast period.

Charting the Growth Trajectory

• Strong growth from $1.02 billion in 2023 to $1.1 billion in 2024.
• Compound annual growth rate (CAGR) of 8.0%.
• Factors: Patent expiration, increased healthcare expenditure, strong pipeline of drugs.

Forecasting Future Growth: A Closer Look

• Rapid expansion to $1.66 billion in 2028.
• CAGR of 10.7%.
• Drivers: Aging population, increased healthcare access.
• Emerging trends: Extensive investment in R&D, focus on M&A strategies.

Neutropenia Prevalence Drives Growth In The Filgrastim Biosimilar Market

• Impact of neutropenia prevalence on market growth.
• Functionality of filgrastim biosimilars in treating neutropenia.
• Prevalence statistics from the National Center for Biotechnology Information.
• Market response to rising prevalence of neutropenia.

View More On The Filgrastim Biosimilars Market Report 2024 – https://www.thebusinessresearchcompany.com/report/filgrastim-biosimilar-global-market-report

Amneal Pharmaceuticals’ Fylnetra Marks A New Era Of Accessible Healthcare With Recombinant DNA Technology

• Utilization of recombinant DNA technology for biosimilar production.
• Introduction of Fylnetra by Amneal Pharmaceuticals.
• Features and benefits of Fylnetra in treating neutropenia.
• Contribution of Fylnetra to accessible healthcare.

Biocon Biologics’ Transformative Acquisition Of Viatris Inc.

• Biocon Biologics’ strategic acquisition of Viatris Inc.
• Enhancement of global biosimilars enterprise.
• Benefits and synergies of the acquisition for both parties.
• Viatris Inc.’s role in the development of biosimilars.

Market Segmentation and Regional Insights

• Segmentation by type of manufacturing, application, and distribution channel.
• Dominance of North America in 2023.
• Expected growth in the Middle East during the forecast period.
• Regional dynamics and market projections.

In conclusion, the filgrastim biosimilars market is experiencing robust growth driven by factors such as the rising prevalence of neutropenia and advancements in biosimilar technologies. With a focus on innovation and strategic partnerships, major players are poised to capitalize on the increasing demand for effective and accessible treatments, ensuring improved healthcare outcomes for patients globally.

Request A Sample Of The Global Filgrastim Biosimilars Market Report 2024:
https://www.thebusinessresearchcompany.com/sample_request?id=4016&type=smp